2 citations
,
August 2013 in “The Lancet. Diabetes & endocrinology” The FDA rejected a testosterone drug again due to safety concerns.
2 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib improves hair regrowth in alopecia areata over 24 months.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.
2 citations
,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
May 2017 in “Journal of The American Academy of Dermatology” An intact skin barrier is crucial to prevent infection in cases of tether-induced tenosynovitis.
July 2025 in “The Journal of Dermatology” Ritlecitinib has common side effects like headache and acne, and unexpected ones like diabetes and thyroid issues.
August 2025 in “Scientific Electronic library online (Sciences Carlos III Health Institute)” Tofacitinib can help regrow hair in about 50% of people with moderate-severe alopecia areata.
3 citations
,
October 2024 in “Frontiers in Pharmacology” Compounds from Pterocarpus indicus may help treat benign prostatic hyperplasia by stopping cell growth.
September 2023 in “International Journal of Applied Pharmaceutics” The formulated gel is a promising treatment for alopecia areata.
September 2024 in “Journal of the American Academy of Dermatology” AH-001 could be a safer and more effective treatment for hair loss.
November 2023 in “Dermatologica sinica/Zhōnghuá pífūkē yīxué zázhì” Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.
234 citations
,
September 2004 in “Clinical cancer research” BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.
Baricitinib may effectively treat oral lichen planus.
4 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
1 citations
,
October 2024 in “Journal of King Saud University - Science” Tridax procumbens extracts may help treat cancer due to their strong anticancer and antioxidant properties.
5 citations
,
September 2011 in “Bioorganic & Medicinal Chemistry Letters” Pfizer found that pantolactam-based compounds can reduce sebum (skin oil) production when applied topically.
2 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
Baricitinib helps regrow hair in teens with severe alopecia areata.
February 2020 in “Oncology Times” Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.
130 citations
,
February 2018 in “Journal of Investigative Dermatology” Tofacitinib may help treat severe hair loss, but more research is needed.
1 citations
,
September 2022 in “International Journal of Trichology” Tofacitinib can be effective in treating hair loss caused by alopecia areata.
25 citations
,
May 2018 in “Clinical & Translational Oncology” New melanoma treatments can cause skin side effects, including skin cancer and rashes, but combining treatments may reduce these risks.
March 2026 in “Tissue Engineering and Regenerative Medicine” Dopamine-modified adhesives are improving for sticking tissues underwater.
April 2026 in “Case Reports in Dermatology” Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.
January 2026 in “Dermatology Reports” Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.
December 2024 in “Journal of Cancer Therapy and Research” Artocarpus heterophyllus seed extract may help treat prostate inflammation without side effects.
November 2023 in “Annales de dermatologie et de vénéréologie, FMC” Baricitinib effectively treats severe alopecia for up to 104 weeks.
7 citations
,
September 2024 in “The Journal of Dermatology” Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
Vismodegib effectively treats advanced basal cell carcinoma but requires careful management of serious side effects.
1 citations
,
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.